Effects of the CYP2D6☆10 allele on the steady-state plasma concentrations of aripiprazole and its active metabolite, dehydroaripiprazole in Japanese patients with schizophrenia

被引：0
|
作者：
Suzuki, T. [1 ]
Mihara, K. [1 ]
Nagai, G. [1 ]
Nakamura, A. [1 ]
Nemoto, K. [1 ]
Kagawa, S. [1 ]
Uno, T. [1 ]
Kondo, T. [1 ]
机构：
[1] Univ Ryukyus, Fac Med, Nakagami Country, Okinawa, Japan
来源：
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY | 2010年 / 13卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：207 / 207
页数：1
相关论文
共 50 条
  • [1] Effects of the CYP2D6*10 Allele on the Steady-State Plasma Concentrations of Aripiprazole and Its Active Metabolite, Dehydroaripiprazole, in Japanese Patients With Schizophrenia
    Suzuki, Takeshi
    Mihara, Kazuo
    Nakamura, Akifumi
    Nagai, Goyo
    Kagawa, Shoko
    Nemoto, Kenji
    Ohta, Ikuya
    Arakaki, Hajime
    Uno, Tsukasa
    Kondo, Tsuyoshi
    THERAPEUTIC DRUG MONITORING, 2011, 33 (01) : 21 - 24
  • [2] Effects of Genetic Polymorphisms of CYP2D6, CYP3A5, and ABCB1 on the Steady-State Plasma Concentrations of Aripiprazole and Its Active Metabolite, Dehydroaripiprazole, in Japanese Patients With Schizophrenia
    Suzuki, Takeshi
    Mihara, Kazuo
    Nakamura, Akifumi
    Kagawa, Shoko
    Nagai, Goyo
    Nemoto, Kenji
    Kondo, Tsuyoshi
    THERAPEUTIC DRUG MONITORING, 2014, 36 (05) : 651 - 655
  • [3] Effects of the CYP2D6*10 allele on the steady-state plasma concentrations of haloperidol and reduced haloperidol in Japanese patients with schizophrenia
    Mihara, K
    Suzuki, A
    Kondo, T
    Yasui, N
    Furukori, H
    Nagashima, U
    Otani, K
    Kaneko, S
    Inoue, Y
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1999, 65 (03) : 291 - 294
  • [4] Impact of the CYP2D6 genotype on steady-state serum concentrations of aripiprazole and dehydroaripiprazole
    Magnhild Hendset
    Monica Hermann
    Hilde Lunde
    Helge Refsum
    Espen Molden
    European Journal of Clinical Pharmacology, 2007, 63 : 1147 - 1151
  • [5] Impact of CYP2D6 genotype on steady-state serum concentrations of aripiprazole and dehydroaripiprazole
    Hendset, Magnhild
    Hermann, Monica
    Lunde, Hilde
    Refsum, Helge
    Molden, Espen
    THERAPEUTIC DRUG MONITORING, 2007, 29 (04) : 478 - 478
  • [6] Effects of Paroxetine on Plasma Concentrations of Aripiprazole and Its Active Metabolite, Dehydroaripiprazole, in Japanese Patients With Schizophrenia
    Nemoto, Kenji
    Mihara, Kazuo
    Nakamura, Akifumi
    Nagai, Goyo
    Kagawa, Shoko
    Suzuki, Takeshi
    Kondo, Tsuyoshi
    THERAPEUTIC DRUG MONITORING, 2012, 34 (02) : 188 - 192
  • [7] Impact of the CYP2D6 genotype on steady-state serum concentrations of aripiprazole and dehydroaripiprazole
    Hendset, Magnhild
    Hermann, Monica
    Lunde, Hilde
    Refsum, Helge
    Molden, Espen
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2007, 63 (12) : 1147 - 1151
  • [8] Effects of various CYP2D6 genotypes on the steady-state plasma concentrations of risperidone and its active metabolite, 9-hydroxyrisperidone, in Japanese patients with schizophrenia
    Mihara, K
    Kondo, T
    Yasui-Furukori, N
    Suzuki, A
    Ishida, M
    Ono, S
    Kubota, T
    Iga, T
    Takarada, Y
    de Vries, R
    Kaneko, S
    THERAPEUTIC DRUG MONITORING, 2003, 25 (03) : 287 - 293
  • [9] Effects of Escitalopram on Plasma Concentrations of Aripiprazole and its Active Metabolite, Dehydroaripiprazole, in Japanese Patients
    Nemoto, K.
    Mihara, K.
    Nakamura, A.
    Nagai, G.
    Kagawa, S.
    Suzuki, T.
    Kondo, T.
    PHARMACOPSYCHIATRY, 2014, 47 (03) : 101 - 104
  • [10] Effects of thioridazine, an inhibitor of CYP2D6, on the steady-state plasma concentrations of the enantiomers of mianserin and its active metabolite, desmethylmianserin, in depressed Japanese patients
    Yasui, N
    Tybring, G
    Otani, K
    Mihara, K
    Suzuki, A
    Svensson, JO
    Kaneko, S
    PHARMACOGENETICS, 1997, 7 (05): : 369 - 374
12345